Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
Peter A. Riedell, Wei‐Ting Hwang, Loretta J. Nastoupil, Martina Pennisi, Joseph P. McGuirk, Richard T. Maziarz, Veronika Bachanová, Olalekan O. Oluwole, Jamie Brower, Oscar A. Flores, Nausheen Ahmed, Levanto Schachter, Kharmen Bharucha, Bhagirathbhai Dholaria, Stephen J. Schuster, Miguel‐Angel Perales, Michael R. Bishop, David L. Porter
Topics & Concepts
MedicineCytokine release syndromeApheresisInternal medicineRefractory (planetary science)Salvage therapyOncologyClinical trialChimeric antigen receptorGastroenterologyImmunotherapyCancerChemotherapyPlateletAstrobiologyPhysicsCAR-T cell therapy researchIntegrated Circuits and Semiconductor Failure AnalysisAdvancements in Semiconductor Devices and Circuit Design